Literature DB >> 33751207

Linking proteomic alterations in schizophrenia hippocampus to NMDAr hypofunction in human neurons and oligodendrocytes.

Giuliana S Zuccoli1, Guilherme Reis-de-Oliveira1, Bruna Garbes2, Peter Falkai3, Andrea Schmitt3, Helder I Nakaya4, Daniel Martins-de-Souza5,6,7,8.   

Abstract

Glutamatergic neurotransmission dysfunction and the early involvement of the hippocampus have been proposed to be important aspects of the pathophysiology of schizophrenia. Here, we performed proteomic analysis of hippocampus postmortem samples from schizophrenia patients as well as neural cells-neurons and oligodendrocytes-treated with MK-801, an NMDA receptor antagonist. There were similarities in processes such as oxidative stress and apoptotic process when comparing hippocampus samples with MK-801-treated neurons, and in proteins synthesis when comparing hippocampus samples with MK-801-treated oligodendrocytes. This reveals that studying the effects of glutamatergic dysfunction in different neural cells can contribute to a better understanding of what it is observed in schizophrenia patients' postmortem brains.
© 2021. Springer-Verlag GmbH Germany, part of Springer Nature.

Entities:  

Keywords:  Hippocampus; MK-801; Neurons; Oligodendrocytes; Proteome

Mesh:

Substances:

Year:  2021        PMID: 33751207     DOI: 10.1007/s00406-021-01248-w

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  58 in total

1.  Comparison of ketamine-induced thought disorder in healthy volunteers and thought disorder in schizophrenia.

Authors:  C M Adler; A K Malhotra; I Elman; T Goldberg; M Egan; D Pickar; A Breier
Journal:  Am J Psychiatry       Date:  1999-10       Impact factor: 18.112

Review 2.  Cell biology of the hippocampal formation in schizophrenia.

Authors:  D R Weinberger
Journal:  Biol Psychiatry       Date:  1999-02-15       Impact factor: 13.382

Review 3.  Glutamate receptors and transporters in the hippocampus in schizophrenia.

Authors:  Paul J Harrison; Amanda J Law; Sharon L Eastwood
Journal:  Ann N Y Acad Sci       Date:  2003-11       Impact factor: 5.691

4.  Evidence of dysfunction of a prefrontal-limbic network in schizophrenia: a magnetic resonance imaging and regional cerebral blood flow study of discordant monozygotic twins.

Authors:  D R Weinberger; K F Berman; R Suddath; E F Torrey
Journal:  Am J Psychiatry       Date:  1992-07       Impact factor: 18.112

Review 5.  The glutamate hypothesis of schizophrenia: evidence from human brain tissue studies.

Authors:  Wei Hu; Matthew L MacDonald; Daniel E Elswick; Robert A Sweet
Journal:  Ann N Y Acad Sci       Date:  2014-10-14       Impact factor: 5.691

Review 6.  Glutamatergic abnormalities in schizophrenia: a review of proton MRS findings.

Authors:  Eline M P Poels; Lawrence S Kegeles; Joshua T Kantrowitz; Daniel C Javitt; Jeffrey A Lieberman; Anissa Abi-Dargham; Ragy R Girgis
Journal:  Schizophr Res       Date:  2014-01-11       Impact factor: 4.939

Review 7.  The hippocampal formation in schizophrenia.

Authors:  Carol A Tamminga; Ana D Stan; Anthony D Wagner
Journal:  Am J Psychiatry       Date:  2010-09-01       Impact factor: 18.112

8.  Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses.

Authors:  J H Krystal; L P Karper; J P Seibyl; G K Freeman; R Delaney; J D Bremner; G R Heninger; M B Bowers; D S Charney
Journal:  Arch Gen Psychiatry       Date:  1994-03

Review 9.  Glutamatergic dysfunction in schizophrenia: from basic neuroscience to clinical psychopharmacology.

Authors:  Rodrigo D Paz; Sonia Tardito; Marco Atzori; Kuei Y Tseng
Journal:  Eur Neuropsychopharmacol       Date:  2008-07-23       Impact factor: 4.600

Review 10.  Glutamate and schizophrenia: phencyclidine, N-methyl-D-aspartate receptors, and dopamine-glutamate interactions.

Authors:  Daniel C Javitt
Journal:  Int Rev Neurobiol       Date:  2007       Impact factor: 3.230

View more
  3 in total

1.  Modeling Schizophrenia In Vitro: Challenges and Insights on Studying Brain Cells.

Authors:  Gabriela Maciel Vieira; Fernanda Crunfli; Caroline Brandão-Teles; Giuliana S Zuccoli; Bradley J Smith
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

2.  Postmortem Brains: What Can Proteomics Tell us About the Sources of Schizophrenia?

Authors:  Guilherme Reis-de-Oliveira; Bradley J Smith; Daniel Martins-de-Souza
Journal:  Adv Exp Med Biol       Date:  2022       Impact factor: 3.650

3.  Reduced number of satellite oligodendrocytes of pyramidal neurons in layer 5 of the prefrontal cortex in schizophrenia.

Authors:  Natalya S Kolomeets; Natalya A Uranova
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2021-11-25       Impact factor: 5.760

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.